N-Acetyl Cysteine in Pathologic Skin Picking

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the proposed study is to evaluate the comparative efficacy of N-acetyl cysteine to placebo in pathologic skin picking. Thirty subjects with pathologic skin picking will receive 12 weeks of double-blind treatment with N-acetyl cysteine or matching placebo. The hypothesis to be tested is that N-acetyl cysteine will be more effective than placebo in patients with pathologic skin picking. The proposed study will provide needed data on the treatment of an often disabling disorder that currently lacks a clearly effective treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

1. Men and women age 18-65;

2. Current diagnosis of pathologic skin picking as determined by criteria proposed by Arnold et al. (2001) for at least 6 months duration

Exclusion Criteria:

1. Unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination;

2. History of seizures;

3. Myocardial infarction within 6 months;

4. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;

5. Need for medication other than NAC with possible psychotropic effects or unfavorable interactions with NAC;

6. Clinically significant suicidality (score or 3 or 4 on item 3 of the Hamilton Depression Rating Scale);

7. Lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;

8. Current or recent (past 3 months) DSM-IV substance abuse or dependence;

9. Illegal substance use within 2 weeks of study initiation;

10. Initiation of pharmacotherapy, psychotherapy, or behavior therapy from a mental health professional within 3 months prior to study baseline for the treatment of pathologic skin picking;

11. Previous treatment with N-acetyl cysteine;

12. Treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;

13. Asthma (given possible worsening of asthma due to NAC)